Morgan Stanley’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

Morgan Stanley’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,022	Closed	-$29	–	8090
2024 Q2	$29	Sell	1,022 -718,026	-100%	-$38.6K	﹤0.01%	7686
2024 Q1	$64.7K	Sell	719,048 -719,088	-50%	-$68.7K	﹤0.01%	6127
2023 Q4	$151K	Buy	1,438,136 +719,268	+100%	+$106K	﹤0.01%	6044
2023 Q3	$162K	Hold	718,868	–	–	﹤0.01%	5678
2023 Q2	$188K	Hold	718,868	–	–	﹤0.01%	5671
2023 Q1	$129K	Hold	718,868	–	–	﹤0.01%	5904
2022 Q4	$144K	Sell	718,868 -400	-0.1%	-$172	﹤0.01%	5805
2022 Q3	$518K	Hold	719,268	–	–	﹤0.01%	5252
2022 Q2	$381K	Hold	719,268	–	–	﹤0.01%	5549
2022 Q1	$633K	Hold	719,268	–	–	﹤0.01%	5270
2021 Q4	$1.61M	Buy	719,268 +1,001	+0.1%	+$3.24K	﹤0.01%	4736
2021 Q3	$2.44M	Buy	+718,267	New	+$2.56M	﹤0.01%	4404

Other funds holding DNA.WS

Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return

SBLIC

Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return

HIA

Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Morgan Stanley's DNA.WS Position: Q3 2024 in Review

Morgan Stanley sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q3 2024, closing a stake of 1,022 shares — an estimated $29 sold.

Morgan Stanley first reported a position in DNA.WS in Q3 2021 and held it in 12 quarters. The position peaked at $2.44M in Q3 2021. 5 funds tracked by Wall St. Rank hold DNA.WS as of Q3 2024.

Morgan Stanley reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q3 2024 after selling out during the quarter.
Morgan Stanley sold 1,022 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q3 2024, an estimated $29.
Morgan Stanley first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q3 2021 and held it in 12 quarters.
Morgan Stanley's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $2.44M in Q3 2021.
5 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q3 2024.

Based on Morgan Stanley's 13F filing for Q3 2024, filed 14 Nov 2024.